Title |
Toward onset prevention of cognitive decline in adults with Down syndrome (the TOP-COG study): study protocol for a randomized controlled trial
|
---|---|
Published in |
Trials, June 2014
|
DOI | 10.1186/1745-6215-15-202 |
Pubmed ID | |
Authors |
Sally-Ann Cooper, Muriel Caslake, Jonathan Evans, Angela Hassiotis, Andrew Jahoda, Alex McConnachie, Jill Morrison, Howard Ring, John Starr, Ciara Stiles, Frank Sullivan |
Abstract |
Early-onset dementia is common in Down syndrome adults, who have trisomy 21. The amyloid precursor protein gene is on chromosome 21, and so is over-expressed in Down syndrome, leading to amyloid b (Ab) over-production, a major upstream pathway leading to Alzheimer disease (AD). Statins (microsomal 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors), have pleiotropic effects including potentially increasing brain amyloid clearance, making them plausible agents to reduce AD risk. Animal models, human observational studies, and small scale trials support this rationale, however, there are no AD primary prevention trials in Down syndrome adults. In this study we study aim to inform the design of a full-scale primary prevention trial. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 50% |
Venezuela, Bolivarian Republic of | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Canada | 1 | <1% |
Brazil | 1 | <1% |
Unknown | 169 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 29 | 17% |
Researcher | 16 | 9% |
Student > Ph. D. Student | 14 | 8% |
Student > Bachelor | 13 | 8% |
Student > Doctoral Student | 12 | 7% |
Other | 32 | 19% |
Unknown | 55 | 32% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 34 | 20% |
Psychology | 23 | 13% |
Nursing and Health Professions | 22 | 13% |
Neuroscience | 6 | 4% |
Social Sciences | 6 | 4% |
Other | 20 | 12% |
Unknown | 60 | 35% |